The -omics era: Proteomics and lipidomics in vascular research

Atherosclerosis

Volumn 221, Issue 1, 2012, Pages 12-17

  Didangelos, Athanasios ^a   Stegemann, Christin ^a   Mayr, Manuel ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Atherosclerosis; Biomarkers; Lipoproteins; Matrix; Metabolomics; Proteomics

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN B100; CELL PROTEIN; COLLAGEN; ELASTIN; FIBRONECTIN; LAMININ; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MATRIX METALLOPROTEINASE; MESSENGER RNA; PROTEOGLYCAN; PROTEOME; SCLEROPROTEIN; TOLL LIKE RECEPTOR;

ATHEROSCLEROSIS; BLOOD VESSEL WALL; EXTRACELLULAR MATRIX; HUMAN; INFLAMMATION; LIPID ANALYSIS; LIPID OXIDATION; LIPIDOMICS; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONTENT; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN ISOLATION; PROTEIN LIPID INTERACTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; PROTEOMICS; REVIEW; SMOOTH MUSCLE FIBER;

ATHEROSCLEROSIS; BIOMEDICAL RESEARCH; BLOOD VESSELS; EXTRACELLULAR MATRIX; HUMANS; LIPID METABOLISM; MALE; MASS SPECTROMETRY; METABOLOMICS; PROTEOMICS;

EID: 84857033576     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.09.043     Document Type: Review

References (57)

1. Williams K.J., Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995, 15:551-561.
2. Williams K.J., Tabas I. The response-to-retention hypothesis of atherogenesis reinforced. Curr Opin Lipidol 1998, 9:471-474.
3. Tabas I., Williams K.J., Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 2007, 116:1832-1844.
4. Didangelos A., Simper D., Monaco C., et al. Proteomics of acute coronary syndromes. Curr Atheroscler Rep 2009, 11:188-195.
5. Gygi S.P., Rochon Y., Franza B.R., et al. Correlation between protein and mRNA abundance in yeast. Mol Cell Biol 1999, 19:1720-1730.
6. Van Eyk J.E. Overview: the maturing of proteomics in cardiovascular research. Circ Res 2011, 108:490-498.
7. You S.A., Archacki S.R., Angheloiu G., et al. Proteomic approach to coronary atherosclerosis shows ferritin light chain as a significant marker: evidence consistent with iron hypothesis in atherosclerosis. Physiol Genomics 2003, 13:25-30.
8. Lepedda A.J., Cigliano A., Cherchi G.M., et al. A proteomic approach to differentiate histologically classified stable and unstable plaques from human carotid arteries. Atherosclerosis 2009, 203:112-118.
9. Martin-Ventura J.L., Duran M.C., Blanco-Colio L.M., et al. Identification by a differential proteomic approach of heat shock protein 27 as a potential marker of atherosclerosis. Circulation 2004, 110:2216-2219.
10. Barderas M.G., Tunon J., Darde V.M., et al. Circulating human monocytes in the acute coronary syndrome express a characteristic proteomic profile. J Proteome Res 2007, 6:876-886.
11. Mayr M., Chung Y.L., Mayr U., et al. Proteomic and metabolomic analyses of atherosclerotic vessels from apolipoprotein E-deficient mice reveal alterations in inflammation, oxidative stress, and energy metabolism. Arterioscler Thromb Vasc Biol 2005, 25:2135-2142.
12. Wang Z., Klipfell E., Bennett B.J., et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011, 472:57-63.
13. Mayr M., Zampetaki A., Sidibe A., et al. Proteomic and metabolomic analysis of smooth muscle cells derived from the arterial media and adventitial progenitors of apolipoprotein E-deficient mice. Circ Res 2008, 102:1046-1056.
14. Wu J., Liu W., Sousa E., et al. Proteomic identification of endothelial proteins isolated in situ from atherosclerotic aorta via systemic perfusion. J Proteome Res 2007, 6:4728-4736.
15. Mayr M., Grainger D., Mayr U., et al. Proteomics, metabolomics, and immunomics on microparticles derived from human atherosclerotic plaques. Circ Cardiovasc Genet 2009, 2:379-388.
16. Puntmann V.O., Taylor P.C., Mayr M. Coupling vascular and myocardial inflammatory injury into a common phenotype of cardiovascular dysfunction: systemic inflammation and aging-a mini-review. Gerontology 2011, 57:295-303.
17. Talusan P., Bedri S., Yang S., et al. Analysis of intimal proteoglycans in atherosclerosis-prone and atherosclerosis-resistant human arteries by mass spectrometry. Mol Cell Proteomics 2005, 4:1350-1357.
18. de Kleijn D.P., Moll F.L., Hellings W.E., et al. Local atherosclerotic plaques are a source of prognostic biomarkers for adverse cardiovascular events. Arterioscler Thromb Vasc Biol 2009, 30:612-619.
19. Meuwese M.C., Stroes E.S., Hazen S.L., et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol 2007, 50:159-165.
20. Nambi V. The use of myeloperoxidase as a risk marker for atherosclerosis. Curr Atheroscler Rep 2005, 7:127-131.
21. Peuhkurinen K.J., Risteli L., Melkko J.T., et al. Thrombolytic therapy with streptokinase stimulates collagen breakdown. Circulation 1991, 83:1969-1975.
22. Bonnet J., Garderes P.E., Aumailley M., et al. Serum type III procollagen peptide levels in coronary artery disease (a marker of atherosclerosis). Eur J Clin Invest 1988, 18:18-21.
23. Blankenberg S., Rupprecht H.J., Poirier O., et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003, 107:1579-1585.
24. Beaudeux J.L., Giral P., Bruckert E., et al. Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 as potential markers of carotid atherosclerosis in infraclinical hyperlipidemia. Atherosclerosis 2003, 169:139-146.
25. Wilson R., Diseberg A.F., Gordon L., et al. Comprehensive profiling of cartilage extracellular matrix formation and maturation using sequential extraction and label-free quantitative proteomics. Mol Cell Proteomics 2010, 9:1296-1313.
26. Didangelos A., Yin X., Mandal K., et al. Proteomics characterization of extracellular space components in the human aorta. Mol Cell Proteomics 2010, 9:2048-2062.
27. Didangelos A., Yin X., Mandal K., et al. Extracellular matrix composition and remodeling in human abdominal aortic aneurysms: a proteomics approach. Mol Cell Proteomics 2011.
28. Galeano N.F., Milne R., Marcel Y.L., et al. Apoprotein B structure and receptor recognition of triglyceride-rich low density lipoprotein (LDL) is modified in small LDL but not in triglyceride-rich LDL of normal size. J Biol Chem 1994, 269:511-519.
29. Skalen K., Gustafsson M., Rydberg E.K., et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002, 417:750-754.
30. Kolodgie F.D., Burke A.P., Farb A., et al. Differential accumulation of proteoglycans and hyaluronan in culprit lesions: insights into plaque erosion. Arterioscler Thromb Vasc Biol 2002, 22:1642-1648.
31. Olin-Lewis K., Krauss R.M., La Belle M., et al. ApoC-III content of apoB-containing lipoproteins is associated with binding to the vascular proteoglycan biglycan. J Lipid Res 2002, 43:1969-1977.
32. Flood C., Gustafsson M., Pitas R.E., et al. Molecular mechanism for changes in proteoglycan binding on compositional changes of the core and the surface of low-density lipoprotein-containing human apolipoprotein B100. Arterioscler Thromb Vasc Biol 2004, 24:564-570.
33. Willner E.L., Tow B., Buhman K.K., et al. Deficiency of acyl CoA:cholesterol acyltransferase 2 prevents atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A 2003, 100:1262-1267.
34. Monaco C., Gregan S.M., Navin T.J., et al. Toll-like receptor-2 mediates inflammation and matrix degradation in human atherosclerosis. Circulation 2009, 120:2462-2469.
35. Cole J.E., Navin T.J., Cross A.J., et al. Unexpected protective role for Toll-like receptor 3 in the arterial wall. Proc Natl Acad Sci U S A 2011, 108:2372-2377.
36. Seimon T.A., Nadolski M.J., Liao X., et al. Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab 2010, 12:467-482.
37. Sun Y., Ishibashi M., Seimon T., et al. Free cholesterol accumulation in macrophage membranes activates Toll-like receptors and p38 mitogen-activated protein kinase and induces cathepsin K. Circ Res 2009, 104:455-465.
38. Ekroos K., Janis M., Tarasov K., et al. Lipidomics: a tool for studies of atherosclerosis. Curr Atheroscler Rep 2010, 12:273-281.
39. Lagarde M., Geloen A., Record M., et al. Lipidomics is emerging. Biochim Biophys Acta 2003, 1634:61.
40. Hiukka A., Stahlman M., Pettersson C., et al. ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan. Diabetes 2009, 58:2018-2026.
41. Davis B., Koster G., Douet L.J., et al. Electrospray ionization mass spectrometry identifies substrates and products of lipoprotein-associated phospholipase A2 in oxidized human low density lipoprotein. J Biol Chem 2008, 283:6428-6437.
42. Mallat Z., Nakamura T., Ohan J., et al. The relationship of hydroxyeicosatetraenoic acids and F2-isoprostanes to plaque instability in human carotid atherosclerosis. J Clin Invest 1999, 103:421-427.
43. Ravandi A., Babaei S., Leung R., et al. Phospholipids and oxophospholipids in atherosclerotic plaques at different stages of plaque development. Lipids 2004, 39:97-109.
44. Thukkani A.K., McHowat J., Hsu F.F., et al. Identification of alpha-chloro fatty aldehydes and unsaturated lysophosphatidylcholine molecular species in human atherosclerotic lesions. Circulation 2003, 108:3128-3133.
45. Manicke N.E., Nefliu M., Wu C., et al. Imaging of lipids in atheroma by desorption electrospray ionization mass spectrometry. Anal Chem 2009, 81:8702-8707.
46. Han X., Gross R.W. Shotgun lipidomics: electrospray ionization mass spectrometric analysis and quantitation of cellular lipidomes directly from crude extracts of biological samples. Mass Spectrom Rev 2005, 24:367-412.
47. Stegemann C., Drozdov I., Shalhoub J., et al. Comparative lipidomics profiling of human atherosclerotic plaques. Circ Cardiovasc Genet 2011, 4:232-242.
48. Serhan C.N., Chiang N., Van Dyke T.E. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008, 8:349-361.
49. Spite M., Serhan C.N. Lipid signatures of unstable atheromas: fossils or a step toward personalized lipidomics-metabolomics?. Circ Cardiovasc Genet 2011, 4:215-217.
50. Meikle P.J., Wong G., Tsorotes D., et al. Plasma lipidomic analysis of stable and unstable coronary artery disease. Arterioscler Thromb Vasc Biol 2011.
51. Yin X., Cuello F., Mayr U., et al. Proteomics analysis of the cardiac myofilament subproteome reveals dynamic alterations in phosphatase subunit distribution. Mol Cell Proteomics 2010, 9:497-509.
52. Mayr M., Liem D., Zhang J., et al. Proteomic and metabolomic analysis of cardioprotection: interplay between protein kinase C epsilon and delta in regulating glucose metabolism of murine hearts. J Mol Cell Cardiol 2009, 46:268-277.
53. Huber L.A. Is proteomics heading in the wrong direction?. Nat Rev Mol Cell Biol 2003, 4:74-80.
54. Bligh E.G., Dyer W.J. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959, 37:911-917.
55. Folch J., Ascoli I., Lees M., et al. Preparation of lipide extracts from brain tissue. J Biol Chem 1951, 191:833-841.
56. Sullards M.C., Merrill A.H. Analysis of sphingosine 1-phosphate, ceramides, and other bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry. Sci STKE 2001, pl1.
57. Ejsing C.S., Duchoslav E., Sampaio J., et al. Automated identification and quantification of glycerophospholipid molecular species by multiple precursor ion scanning. Anal Chem 2006, 78:6202-6214.